A condensed-cyclic compound represented by Formula 1 and an organic light-emitting device including the condensed-cyclic compound. ##STR00001##
wherein R.sub.1 to R.sub.10 are defined as in the specification.

A condensed-cyclic compound represented by Formula 1 and an organic light-emitting device including the condensed-cyclic compound. ##STR00001##
wherein R.sub.1 to R.sub.10 are defined as in the specification.

A quencher is disclosed having a compound represented by the following general formula (1):

##STR00001##

wherein R.sub.5 each independently represent a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an amino group having a substituent or not having a substituent, a hydroxy group, an aryl group, an aryloxy group, or an arylalkyl group; R.sub.6 represents a group having a polymerizable unsaturated group, a hydroxy group, or the like; Y.sub.1 represents an oxygen atom, or the like; An.sup.− represents an anion; Ar.sub.1 represents a specific ring structure; * and ** represent binding positions; Ar.sub.2 represents a benzene ring, a naphthalene ring, or an anthracene ring; n.sub.1 represents a specific integer;
and the following structure (1-10) in the general formula (1) is an asymmetric structure;

##STR00002##

(wherein R.sub.5, Y.sub.1, Ar.sub.1, Ar.sub.2, n.sub.1, * and ** are the same as described above.).

A quencher is disclosed having a compound represented by the following general formula (1):

##STR00001##

wherein R.sub.5 each independently represent a halogen atom, an alkyl group, an alkoxy group, an alkylthio group, an amino group having a substituent or not having a substituent, a hydroxy group, an aryl group, an aryloxy group, or an arylalkyl group; R.sub.6 represents a group having a polymerizable unsaturated group, a hydroxy group, or the like; Y.sub.1 represents an oxygen atom, or the like; An.sup.− represents an anion; Ar.sub.1 represents a specific ring structure; * and ** represent binding positions; Ar.sub.2 represents a benzene ring, a naphthalene ring, or an anthracene ring; n.sub.1 represents a specific integer;
and the following structure (1-10) in the general formula (1) is an asymmetric structure;

##STR00002##

(wherein R.sub.5, Y.sub.1, Ar.sub.1, Ar.sub.2, n.sub.1, * and ** are the same as described above.).

The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis). ##STR00001##

The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis). ##STR00001##

The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof ##STR00001## wherein Ar′, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.

The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof ##STR00001## wherein Ar′, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

##STR00001##

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

##STR00001##